Compounds for targeting hepatocytes in vivo

Details Compounds for targeting hepatocytes in vivo Compounds for targeting hepatocytes in vivo

2006-07-04

2006-07-04

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S04400A, C530S350000, C424S085100

Reexamination Certificate

active

07071163

ABSTRACT:
We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.

REFERENCES:
patent: 6471957 (2002-10-01), Sim et al.
Carlsson, J. et al. Biochem. J. 173: 723-737 (1978).
Rensen, P. et al. JBC 276(40): 37577-37584 (2001).
Studier, F.W. et al. Methods in Enzymology 185: 60-89 (1990).
Lutz-Freyermuth, C. et al. PNAS 87: 6393-6397 (1990).
Biessen EAL, et al. “Ligand size is a major determinant of high-affinity binding of fucose- and galactose-exposing (lipo)proteins by the hepatic fucose recepotor.”Biochem J1994 vol. 299 pp. 291-296.
Bijsterbosch MK, et al Native and modified lipoproteins as drug delivery systems.Advanced Drug Delivery Reviews1990 vol. 5 pp. 213-251.
Chiou HC, et al. Gene therapy strategies for the treatment of chronic viral hepatitis.Expert Opinion on Biological Therapy2001 vol. 1 pp. 629-639.
Fiume L, et al. Inhibition of hepatitis viral replication by vidarabine monophosphate conjugated with lactasaminated serum albumin.Lancet1988 vol. 2 pp. 13-15.
Fiume L, et al. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin.J Hepatology1992 vol. 15 pp. 314-322.
Furomoto K, et al. Biliary excretion of polystyrene micropheres depends on the type of receptor-mediated uptake in rat liver.Biochimica et Biophysica Acta2001 vol. 1526 pp. 221-226.
Goldberg J, et al. Erythropoietin mimetics derived from solution phase combinatorial libraries.J Amer Chem Soc2002 vol. 124 pp. 544-555.
Groman EV, et al. Arabinogalactan for hepatic drug delivery.Bioconj Chem1994 vol. 5 pp. 547-556.
High KA. Gene transfer as an approach to treating hemophilia.Circulation Research2001 vol. 88 pp. 137-144.
Koide A, et al. The fibronectin type III domain as a scaffold for novel binding proteins. Journal of Molecular Biology 1998 vol. 284 pp. 1141-1151.
Lee YC, et al. Binding of synthetic oligosaccharides to the hepatic gal/GalNAc lectin.J Biol Chem1983 vol. 258 pp. 199-202.
Meiher DKF, et al. Drug targeting systems for antiviral agents: options and limitations.Antiviral Research1992 vol. 18 pp. 215-258.
Nord K, et al. Binding proteins selected form combinatorial libraries of an alpha-helical bacterial receptor domain.Nature Biotechnology1997 vol. 15 pp. 772-777.
Nord K, et al. A combinatorial libary of an alpha-helical bacterial receptor domain.Protein Engineering1995 vol. 8 pp. 601-608.
Okuno K, et al. Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases.Surg Today1998 vol. 28 pp. 64-69..
Rensen PC, et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytesin vitroandin vivo. Journal of Biological Chemistry2001 vol. 276 pp. 37577-37584.
Rogers JC, et al. Hepatic uptake of proteins coupled to fetuin glycoprotein.Biochem Biophys Res Comm1971 vol. 45 pp. 622-629.
Schlepper-Schafer J, et al. Endocytosis via galactose receptorsin vivo. Ligand size directs uptake by hepatocytes and/or liver marcophages.Experimental Cell Research1986 vol. 165 pp. 494-506.
Severin E, et al. Flow cytometric analysis of mouse hepatocyte ploidy. II. The development of polyploidy pattern in four mice strains with differenct life spans.Cell&Tissue Research1984 vol. 238 pp. 649-652.
Shimada K, et al. Biodistribution of liposomes containing synthetic galactose-terminated diacylglycerol-poly(ethylene)glycols.Biochim Biophys Acta1997 vol. 1326 pp. 329-341.
Sokoloff AV, et al. Specific recognition of protein carboxy-terminal sequences by natural IgM antibodies in normal serum.Molecular Therapy2001 vol. 3 pp. 821-830.
Sokoloff AV, et al. The interactions of peptides with the innate immune system studied with use of T7 phage peptide display.Molecular Therapy2000 vol. 2 pp. 131-139.
Sokoloff AV, et al. “A new peptide ligand that targets particles and heterologous proteins to hepatocytes in vivo.”Molecular Therapy2003 vol. 8 No. 6 pp. 867-872.
Steven AC, et al. Molecular substructure of a viral receptor-recognition protein. The gp17 tail-fiber of bacteriophage T7.Journal of Molecular Biology1988 vol. 200 pp. 351-365.
Studier FW The genetics and physiology of bacteriophage T7.Virology1969 vol. 39 pp. 562-574.
Tomlinson E Theory and practice of site-specific drug delivery.Advance Drug Delivery Reviews1987 vol. 1 pp. 87-98.
van Berkel JC, et al. The effect of a water-soluble tris-galactoside-terminated cholesterol derivative on the fate of low density lipoproteins and liposomes.J Biol Chem1985 vol. 260 pp. 2694-2699.
Vyas SP, et al. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery.Advanced Drug Delivery Reviews2000 vol. 43 pp. 101-164.
Weglarz TC, et al. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes.American Journal of Patholvogy2000 vol. 157 pp. 1963-1974.
Wu J, et al. Targeting hepatocytes for drug and gene delivery pp. emerging novel approaches and applications.Frontiers in Bioscience2002 vol. 7 pp. 717-725.

Affiliated with

Also associated with

Rating

Compounds for targeting hepatocytes in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for targeting hepatocytes in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for targeting hepatocytes in vivo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3610249